UP!

AMRS $2.62   View long term graphs

Amyris, Inc.
Type
Public (NASDAQ: AMRS)
Industry Renewable Fuels, Anti-Malaria, Renewable Chemicals, Renewable Products
Founded 2003
Headquarters Emeryville, California, USA
Key people
John Melo: CEO
Revenue Increase None
Number of employees
300 - 350
Website Amyris.com

Amyris is an integrated renewable products company providing sustainable alternatives to a broad range of petroleum-sourced products and rare materials. Amyris, in conjunction with various partners, is creating industrial scale supplies of vitamins, captive perfume molecules like Ambroxan, a patchouli substitute and Farnesene which can be used in tires, and lubricant, as well as their own beauty care product line using squalane, their substitute molecule for shark oil. Amyris uses its industrial synthetic biology platform to convert plant sugars into a variety of hydrocarbon molecules, flexible building blocks which can be used in a wide range of products. They do this by reengineering yeast so it can recreate complicated molecules. The time to market was reduced four fold after Amyris teamed with Darpa. Amyris is commercializing these products both as renewable ingredients in cosmetics, flavors, fragrances, polymers, lubricants and consumer products, and also as renewable diesel and jet fuels. Amyris Brasil S.A., a subsidiary of Amyris, oversees the establishment and expansion of Amyris’s production in Brazil. Amyris also has fuel distribution capabilities in the United States through its subsidiary, Amyris Fuels LLC. Founded in 2003 and headquartered in Emeryville, Ca, Amyris has raised over $120 million in equity funding to-date, including investments from Royal DSM, Total S.A., Khosla Ventures, Votorantim Novos Negócios, Kleiner Perkins Caufield & Byers, TPG Biotech, and DAG Ventures as well as DARPA. Amyris is opening two more plants in New Zealand and Korea in proximity to sustainable sugar cane crops.

The company went public on NASDAQ in October 2010 (AMRS) but as of January 2013, was trading at less than 30% of its initial offering price due to lack of commercial success in cost-effectively producing "drop in" synthetic transportation fuel, which was to be its initial, major focus. The firm has now focused its attention on higher-priced and higher-margin products that are not in the transportation fuel area

Amyris' technology platform, branded "No Compromise," is focused on providing high performance petroleum-alternatives, using sustainable feedstock such as sugarcane.

Amyris is establishing the partnerships and capabilities needed to bring the renewable diesel fuel to market. A few of these actions include:

Artemisinin is a compound naturally found in the Chinese Sweet Wormwood plant effective in the treatment of malaria. Its production is hampered by difficult climate and agricultural conditions. Institute for OneWorld Health received a grant from the Bill and Melinda Gates Foundation to develop and produce non-seasonal, high-quality, affordable artemisinin, and engaged Amyris Biotechnologies and Sanofi to assist on certain parts of the project, which is near completion, based on technology from UC Berkeley, NRC Canada, and other sources.

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q4 2019 2020-03-12 -0.65 -0.65
Q3 2019 2019-11-07 -0.51 -0.56
Q1 2019 2019-10-07 0.00 -0.82
Q2 2019 2019-10-07 0.00 -0.76
Q4 2018 2019-03-18 -0.66 -0.64
Q3 2018 2018-11-13 -1.13 -1.26
Q2 2018 2018-08-06 0.02 -0.24
Q1 2018 2018-05-14 -1.79 -1.67
Q4 2017 2018-03-15 -0.17 -0.69
Q3 2017 2017-11-14 -1.14 -2.34

Ratings

2016-03-10 Reiterated Rating Cowen and Company Market Perform $2.50 to $2.00
2015-11-10 Initiated Coverage Rodman & Renshaw Buy $4.00
2015-11-10 Initiated Coverage HC Wainwright Buy $4.00
2015-10-12 Reiterated Rating Cowen and Company Hold $2.50
2014-08-08 Boost Price Target Cowen and Company $3.00 to $3.50
2014-05-28 Initiated Coverage Stifel Nicolaus Hold
2014-05-09 Lower Price Target Cowen and Company $3.50 to $3.00
2014-02-26 Upgrade Cowen and Company Underperform to Market Perform $3.00 to $3.50
2014-01-02 Downgrade Cowen and Company Market Perform to Underperform $2.40 to $3.00
2013-11-04 Lower Price Target Cowen and Company $2.75 to $2.40
2012-02-10 Downgrade Deutsche Bank Buy to Hold $20 to $9
2011-11-02 Downgrade Robert W. Baird Outperform to Neutral $25 to $16
2011-01-28 Downgrade Stifel Nicolaus Buy to Hold
2010-11-08 Initiated Stifel Nicolaus Buy $22
2016-03-10 Reiterated Rating Cowen and Company Market Perform $2.50 to $2.00
2015-11-10 Initiated Coverage Rodman & Renshaw Buy $4.00
2015-11-10 Initiated Coverage HC Wainwright Buy $4.00
2015-10-12 Reiterated Rating Cowen and Company Hold $2.50
2014-08-08 Boost Price Target Cowen and Company $3.00 to $3.50

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks
Maxwell (Mauritius) Pte Ltd 62.78%  (49538771) AMRS / PTLA /
DSM International B.V. 11.01%  (8684960) AMRS /
DOERR L JOHN 7.28%  (5746558) AMRS / GOOGL / ZNGA /
Khadder Nicholas General Counsel and Secretary 0.51%  (402020) AMRS / FLDM /
MILLS STEVEN RICHARD Chief Financial Officer 0.50%  (397435) AMRS / BKH /
ASADORIAN RAFFI Chief Financial Officer 0.31%  (241648) ACRX / AMRS /
Diniz Paulo Sergio de Oliveira CEO, Amyris Brasil Ltda. 0.29%  (227000) AMRS /
LEVINSON ARTHUR D 0.28%  (220864) AAPL / AMRS /
MCFERSON SUSANNA CHIEF BUSINESS OFFICER 0.18%  (141841) AMRS /
LOEB GARY SVP, Gen\'l Counsel & Secretary 0.18%  (138389) AKAO / AMRS /
Melo John President and CEO 0.11%  (85304) AMRS /
ALVAREZ EDUARDO Chief Operating Officer 0.09%  (70000) AMRS /
Cherry Joel President of R&D 0.07%  (57785) AMRS /
Georgiadis Mary Margaret Hastings 0.06%  (47000) AMRS / JNY / MAT / MCD /
DUYK GEOFFREY M 0.04%  (29000) AERI / AMRS / EPRS /
Alexander Ralph 0.03%  (27186) AMRS / EPE / SMRT /
PICHETTE PATRICK 0.03%  (26000) AMRS /
Yang Patrick Y 0.03%  (24666) AMRS / CDXS / CLDN / TSO /
KELSEY NICOLE General Counsel and Secretary 0.03%  (21000) AMRS /
Boisseau Philippe 0.02%  (17000) AMRS /
VALIASEK KATHLEEN Chief Financial Officer 0.02%  (14630) AMRS /
Maloney Tina Chief Accounting Officer 0.02%  (12800) AMRS / COO /
WEAVER KAREN Principal Accounting Officer 0.01%  (9091) AMRS /
CHUA NAM HAI DR 0.01%  (9000) AMRS /

Comments